|

Alzheimer's Disease Clinical Trials in Miami, FL

41 recruiting studies within 50 miles

Phase
Trial Phase Dist.
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)Phase 3<1 mi
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's DementiaPhase 2<1 mi
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)Phase 3<1 mi
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's DiseasePhase 2<1 mi
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)Phase 3<1 mi
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)Phase 3<1 mi
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease PsychosisPhase 2<1 mi
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)Phase 3<1 mi
Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's TypePhase 3<1 mi
Alzheimer's Disease Treatment With Combination of 40Hz Light and Cognitive Therapy—<1 mi
ACP-204 in Adults With Alzheimer's Disease PsychosisPhase 2/3<1 mi
[18F]PI-2620 Phase 3 Histopathological StudyPhase 3<1 mi
A Study to Evaluate the Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia (MK-1167-008)Phase 2<1 mi
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease StudiesPhase 3<1 mi
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's DiseasePhase 2<1 mi
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)Phase 3<1 mi
Human Mesenchymal Stem Cells (hMSC) in Behavioral Problems Due to Alzheimer's Disease.Phase 2<1 mi
A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early ADPhase 3<1 mi
A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)Phase 2<1 mi
ExAblate Blood-Brain Barrier (BBB) Disruption for the Treatment of Alzheimer's DiseaseN/A<1 mi
Late Onset Alzheimer's Disease—<1 mi
Allopregnanolone Regenerative Therapeutic for Mild Alzheimer's DiseasePhase 2<1 mi
Combating Alzheimer's Through Sleep and ExerciseN/A<1 mi
Open-label Extension Study in Participants With Early Alzheimer's DiseasePhase 2<1 mi
Personalized Obstructive Sleep Apnea Treatment and Effects on Alzheimer's Disease Biomarkers and Cognition Among BlacksN/A<1 mi
Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia—<1 mi
A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's DiseasePhase 3<1 mi
Clinical Trial on Agitation in Alzheimer's DementiaPhase 2<1 mi
Longitudinal Cognitive Assessment by BoCA—<1 mi
Longitudinal Early-onset Alzheimer's Disease Study Protocol—4 mi
Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3)—4 mi
A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)Phase 29 mi
A Phase Ia/Ib, First-in-human (FIH) Study for Safety, Tolerability, Pharmacokinetics (PK), and Clinical Activity Evaluation of ADEL-Y01Phase 113 mi
A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's DiseasePhase 214 mi
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's DiseasePhase 314 mi
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)Phase 315 mi
Dynamic Light Scattering Ocular Measurement in the Detection of Dementia—34 mi
Neurologic Stem Cell Treatment StudyN/A36 mi
Brain NAD in Alzheimer's Disease—42 mi
Digital Detection of Dementia (D Cubed) Studies: D3N/A42 mi
Pulsed Electromagnetic Field Treatment With Dementia PatientsN/A42 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.